Janux Therapeutics, Inc.
NASDAQ:JANXBiotechnology
-$0.25 today
- Market cap
- $630.80M
- Beta
- 2.52
- P/E (TTM)
- -7.6
- EPS (TTM)
- -$1.83
Volume 0.98M
Average 1.02M
JANX Total Liabilities
Everything the company owes to creditors and other parties.
Janux Therapeutics, Inc.NASDAQ: JANX
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities rises 126.3% from a year ago
Total liabilities stood at $86.69M at the end of Q1 FY2026, up 126.3% from a year earlier and up 71.0% from the prior quarter. Over 3 fiscal years it compounded at +5.4% a year.
Context
- Total liabilities amounted to 8.4% of total assets at the end of Q1 FY2026, up 4.8 pp from a year earlier.
- Total liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +126.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 50.7M USD
- Year-over-year change
- +30.9%
- 4-year CAGR
- +39.2%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 50.7M | +30.9% |
| FY2024 | 2024-12-31 | 38.74M | +7.4% |
| FY2023 | 2023-12-31 | 36.06M | -16.7% |
| FY2022 | 2022-12-31 | 43.27M | +220.6% |
| FY2021 | 2021-12-31 | 13.5M | — |
Total Liabilities vs competitors
How JANX compares with its peers on the latest reported figures
- Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +126.3% is the highest of 10, against a peer median of -11.0%.
- Total liabilities amounts to 8.4% of total assets for JANX, versus a peer median of 11.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $408.7M USD | -41.8% | +7.6% | 24.3% | |
| Mar 2026 | $308.88M USD | -11.0% | +17.3% | 127.6% | |
| Mar 2026 | $196.68M USD | +35.2% | +10.9% | 90.3% | |
| Mar 2026 | €87.55M EUR | -16.7% | -26.2% | 16.1% | |
| Mar 2026 | $86.69M USD | +126.3% | +5.4% | 8.4% | |
| Sep 2026 | $72.06M USD | +43.9% | +28.1% | 10.0% | |
| Sep 2026 | $51.22M USD | +44.5% | +87.6% | 10.1% | |
| Mar 2026 | $39.41M USD | -46.3% | -46.7% | 11.0% | |
| Mar 2026 | $36.81M USD | +32.2% | +15.0% | 9.1% | |
| Mar 2026 | $18.7M USD | -11.7% | +8.2% | 9.1% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding JANX) | — | -11.0% | +10.9% | 11.0% | |
Competitors are the stored peer set for JANX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 35.58M | 51.43M | 19.21M | 430.61M | 52.33M |
| Short-term Investments | 339.38M | 275.59M | 324.82M | 594.57M | 914.23M |
| Net Receivables | 0 | 700K | 2.16M | 5.38M | 6.43M |
| Inventory | 0 | (700K) | 0 | 0 | 0 |
| Other Current Assets | 0 | 5.42M | 0 | 0 | 0 |
| Total Current Assets | 377.02M | 332.44M | 349.24M | 1.03B | 975.89M |
| Property, Plant & Equipment (Net) | 1.6M | 29.37M | 27.84M | 24.15M | 22.25M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 816K | 0 | 0 | 816K |
| Tax Assets | 0 | 0 | 0 | 0 | 5.96M |
| Other Non-current Assets | 1.21M | 1.39M | 3.33M | 3.7M | 2.61M |
| Total Non-current Assets | 2.81M | 31.57M | 31.17M | 27.85M | 31.64M |
| Total Assets | 379.82M | 364.01M | 380.41M | 1.06B | 1.01B |
| Account Payables | 2.46M | 2.16M | 2.42M | 4.03M | 4.97M |
| Short-term Debt | 0 | 0 | 0 | 0 | 2.39M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 5.16M | 5.41M | 1.71M | 0 | 0 |
| Other Current Liabilities | 2.37M | 5.51M | 3.3M | 4.57M | 13.04M |
| Total Current Liabilities | 12.8M | 16.51M | 13.03M | 17.46M | 25M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 5.96M |
| Deferred Revenue (Non-current) | 700K | 2.22M | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 700K | 26.76M | 23.03M | 21.28M | 25.7M |
| Total Liabilities | 13.5M | 43.27M | 36.06M | 38.74M | 50.7M |
| Common Stock | 41K | 42K | 46K | 59K | 60K |
| Retained Earnings | (47.41M) | (110.47M) | (168.76M) | (237.76M) | (351.38M) |
| Accumulated OCI | (270K) | (1.54M) | 665K | 2.16M | 4.32M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 366.33M | 320.74M | 344.35M | 1.02B | 956.82M |
| Total Debt | 194K | 25.31M | 24.54M | 23.03M | 22.14M |
| Net Debt | (35.39M) | (26.12M) | 5.34M | (407.58M) | (30.2M) |
Janux Therapeutics, Inc.
NASDAQ:JANX
Intrinsic Alpha fair value
Locked
Current Price
$10.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.